| Bioactivity | Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs)[1][2]. |
| Name | Reltecimod |
| CAS | 1447799-33-8 |
| Shortening | ASPMLVAYDA |
| Formula | C46H72N10O15S |
| Molar Mass | 1037.19 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reltecimod
CAS: 1447799-33-8 F: C46H72N10O15S W: 1037.19
Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.